Cargando…

Reporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity

Proteasomal protein degradation is a promising target for cancer therapy. Here, we developed a positron emission tomography (PET) technique based on the sodium-iodide symporter (NIS) gene fused with the carboxyl-terminal of ornithine decarboxylase (cODC) that noninvasively images cancer cells with i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jin Hee, Jung, Kyung-Ho, Quach, Cung Hoa Thien, Park, Jin Won, Moon, Seung Hwan, Cho, Young Seok, Lee, Kyung-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095884/ https://www.ncbi.nlm.nih.gov/pubmed/30116045 http://dx.doi.org/10.1038/s41598-018-29642-w

Ejemplares similares

Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy
por: Lee, Jin Hee, et al.
Publicado: (2020)

Mild Alkalization Acutely Triggers the Warburg Effect by Enhancing Hexokinase Activity via Voltage-Dependent Anion Channel Binding
por: Quach, Cung Hoa Thien, et al.
Publicado: (2016)

(89)Zr anti-CD44 immuno-PET monitors CD44 expression on splenic myeloid cells and HT29 colon cancer cells
por: Park, Jin Won, et al.
Publicado: (2021)

Inhibition of aldehyde dehydrogenase 1 enhances the cytotoxic effect of retinaldehyde on A549 cancer cells
por: Park, Jin Won, et al.
Publicado: (2017)

ATP-binding Cassette Transporters Substantially Reduce Estimates of ALDH-positive Cancer Cells based on Aldefluor and AldeRed588 Assays
por: Park, Jin Won, et al.
Publicado: (2019)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling
por: Jung, Kyung-Ho, et al.
Publicado: (2019)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles
por: Jung, Kyung-Ho, et al.
Publicado: (2018)

(99m)Tc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil
por: Park, Jin Won, et al.
Publicado: (2020)

Value of C-11 methionine PET/CT in patients with intracranial germinoma
por: Park, Yong-Jin, et al.
Publicado: (2022)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

(89)Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFκB and JNK Signaling
por: Jung, Kyung-Ho, et al.
Publicado: (2022)

Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen
por: Cho, Hee-Jeong, et al.
Publicado: (2018)

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017)

Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by (89)Zr Immuno-PET
por: Jung, Kyung-Ho, et al.
Publicado: (2022)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Bortezomib inhibits the survival and proliferation of bone marrow stromal cells
por: Kim, Ha-Yon, et al.
Publicado: (2015)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Centiloid method evaluation for amyloid PET of subcortical vascular dementia
por: Yun, Hyuk Jin, et al.
Publicado: (2017)

Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib
por: Örd, Tiit, et al.
Publicado: (2021)

Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma
por: So, Heejune, et al.
Publicado: (2023)

Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis
por: Lee, Hyunjong, et al.
Publicado: (2023)

Genipin enhances the antitumor effect of elesclomol in A549 lung cancer cells by blocking uncoupling protein-2 and stimulating reactive oxygen species production
por: Lee, Jin Hee, et al.
Publicado: (2020)

Proteasome inhibition by bortezomib: A left hook and a right punch
por: Roelofs, Jeroen
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance
por: Wu, Yi-Xin, et al.
Publicado: (2016)

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation
por: Park, Yong-Jin, et al.
Publicado: (2021)

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis
por: Hsu, Sheng-Min, et al.
Publicado: (2015)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Role of (18)F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis
por: Park, Soo Bin, et al.
Publicado: (2018)

Cysteine-specific (89)Zr-labeled anti-CD25 IgG allows immuno-PET imaging of interleukin-2 receptor-α on T cell lymphomas
por: Lee, Jin Hee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pm7ftet230baksja16m1feph4s